Technology vs Product: What B2B Climate and Biotech Buyers Need to Understand First

A technology explains how something becomes possible. A product explains what someone can buy, use or integrate. Science-led companies in climate, energy, materials and biotech often blur the two, most often when the underlying mechanism took years to build. The product has to earn relevance before the technology earns fascination. This piece covers the general pattern across sectors, with a section on food tech. We have written a separate version for industrial biotech.

Technology and product answer different questions

A technology story covers the mechanism, the scientific or engineering step underneath it, why the approach differs from the incumbent and what has been demonstrated so far. A product story covers what the customer receives, where it enters their operation, which specification matters, what it replaces or reduces, what the customer has to change to use it and what evidence supports the promised result.

Both stories are true and both are needed. Trouble starts when a company assumes the first answers the second. A buyer who hears a clear account of a catalytic pathway can still leave the meeting unable to say what they would order, in what volume, against what specification.

Public funders already draw this line. NASA's Technology Readiness Levels describe how mature a technology is. The US Department of Energy pairs that scale with Adoption Readiness Levels, which assess the commercial conditions around a technology to ask whether a market can take it up. It publishes a Commercial Adoption Readiness Assessment Tool for the purpose. A company can score well on technical maturity and still have a product story the buyer cannot follow.

Founders lead with what was hardest to build

If the company spent years on a fermentation process, a sensing system or a new material, that work feels like the centre of the story. The buyer did not live through those years. They arrive with an operational problem.

That problem is usually concrete. They need protein at a set specification and price, a material that passes qualification, a sensor that returns useful readings at the right frequency, or a process that fits the plant without destabilising it. The technical achievement starts to matter at the moment it helps them believe the product can meet those requirements. Before that moment it reads as background.

There is a quieter cost too. A mechanism-first story asks the buyer to do the translation from process to value themselves. Most will do it badly or skip it, and a procurement lead forwarding the deck internally will pass on the confusion with it.

Unibio put the protein first and let the technology prove it

Unibio uses gas fermentation to make protein for animal feed. The process is technically interesting and a real part of the company's advantage. A feed producer still needs to know the product first, meaning what protein is on offer, what it is for, the specifications that matter and the evidence behind them.

When Unibio came to us, its story led with gas fermentation and lost the investors, feed producers and partners who needed to understand the product. In our work with Unibio we repositioned the company around the protein product and used the technology as the evidence behind it, under the line "Lead with protein. Let the technology prove it." We then built the identity and the website so that each of those three audiences meets the product before the process. A product-led story does the translation the buyer would otherwise have to do, in this order.

1. Product
2. Application
3. Value
4. Evidence
5. Mechanism

The product says what is supplied. The application says where it fits. The value says what changes for the customer. The evidence says why that change is credible. The mechanism says why the company can deliver it differently or at scale. The technology stayed in the story and moved to the place where it does the most work, answering the buyer's next doubt about how the product can be made reliably.

The mechanism earns confidence after the offer earns relevance

In industrial biotech and climate technology the mechanism is often part of the moat. Cutting it out would weaken the case. The fix is sequence. The order above suits a buyer who already knows why they are looking. For a buyer who does not yet, the same order compresses to four layers with the customer's moment in front.

1. Moment
2. Product
3. Outcome
4. Proof and mechanism

The moment is what is happening in the customer's world when the product becomes relevant. A feed producer is reformulating. A manufacturer needs a lower-carbon input. A land manager needs evidence before a planting decision. A plant is paying to dispose of a stream that could become an input. The product is what the customer receives, named as plainly as the market allows, whether that is a material, a component, a data product, a unit or an output. The outcome is what changes if it works, in yield, waste, cost, time, reliability, compliance or supply resilience. The proof and mechanism come last, and here the technical story earns its place.

A procurement lead, a technical evaluator, an investor and a scientist will want different depths at that last layer. They should all be looking at the same facts in the same order. We cover the craft of that depth in how to explain a technical product without oversimplifying it.

Platform companies need a first product

Some companies have a real platform with several possible products. The market still needs to meet one of them first. The platform tells an investor why the opportunity could grow large. A specific product tells a customer why there is something worth buying this year.

When every conversation opens with the platform, the company sounds broad before it sounds useful. A sequence that tends to work runs like this.

1. Product wedge
2. Proof
3. Customer value
4. Underlying platform
5. Expansion path

The immediate decision stays concrete and the long-term ambition stays intact, because the platform arrives as an explanation of what comes next.

Food tech and the commercial wedge

Food tech shows the platform problem clearly. A fermentation process, a cell line or a strain library can make many outputs. The Good Food Institute's state of the industry report on fermentation covers meat, seafood, eggs, dairy and ingredients in a single review. A buyer at a food manufacturer sits in one of those directions. An R&D manager reads for performance in a format they recognise. Procurement reads for capacity, price and continuity. A retailer's own-label team reads for claims and labelling.

Regulation makes the product-first order practical. Approvals attach to specific substances and specific uses. In the United States the FDA publishes an inventory of GRAS notices, the filings for substances considered generally recognised as safe for a stated use. Each new output from a platform may need its own route to market. A buyer can only order the output that is cleared, specified and available today.

Koralo, a food-tech company and Brighter Future client, co-ferments microalgae and mycelium. It set out to make a fish alternative. Building that product surfaced bioactivity in the ingredient, and early evidence pointed to a gut health effect. The opportunity widened to a functional ingredient across food, beverage and animal nutrition. Its earlier deck carried four propositions at once, and the fish-alternative story stayed memorable after the commercial centre had moved. When we rebuilt the investor narrative, we kept the seafood story as the route to the discovery and showed the causal path from one product to the larger opportunity.

1. We built this
2. We learnt this
3. The ingredient demonstrated this
4. That evidence opens this larger opportunity

The wider claim holds because the product produced the discovery. Our Koralo case study records the work.

Buyers and investors read the same facts in different orders. An investor may reasonably ask how the first product becomes a multi-product company. A buyer may care about a single application for the life of the contract.

Buyer order: product → application → proof → supply → integration. Investor order: market shift → wedge product → proof → platform → expansion → economics.

Solve that difference with separate routes on the website and separate decks. Give the product and its applications their own pages, with specification sheets, regulatory status and a clear way to request samples.

Test any platform claim before you make it. A real platform has produced more than one commercially relevant output, even at pilot scale, and has a repeatable process for developing the next one. Each new output may still need its own regulatory dossier, downstream processing or plant, and the story should say so. Where the evidence is mostly future possibility, call it possibility. A slide with ten markets and no evidence for nine of them weakens the one market that is real. For the layers a food buyer checks before ordering, see positioning food tech for B2B buyers.

Our biotech branding work applies the same order to industrial and food biotech companies, with the first product in front and the platform as its evidence.

Where the technology should lead

There are real exceptions. A licensing counterparty, a technical partner or a specialist investor may be in the room to evaluate the mechanism itself. In a new category the technology can be the reason the audience turned up at all.

Even then, tie the mechanism to a decision. Say what the technical difference makes possible that was too expensive, too slow or too unreliable before, and which limit of the current approach it removes. Technical depth earns its place when it changes what the reader can conclude. A diagram that only shows the process is decoration. A diagram that shows why yield holds at scale is evidence.

How to test your own story

Give the first page of your website, or the first three slides of your deck, to someone outside the founding team. Ask them to write down five things without help.

1. What they could buy or use.
2. Who it is for.
3. What problem or job it addresses.
4. What result is being claimed.
5. Why they should believe it.

If they can explain the technology and stumble on these, the product is still hidden behind the mechanism. Rewrite the opening so a buyer could answer all five in under a minute, then check that the technical section answers the doubts those answers raise. Science-led companies can keep the technology as impressive as it is and make the commercial object around it easier to see.

Sources and further reading

• Commercial Adoption Readiness Assessment Tool (CARAT), U.S. Department of Energy, 2023
• Adoption Readiness Assessment, U.S. Department of Energy, 2025
• Commercialization and Pathways to Commercial Liftoff, U.S. Department of Energy, accessed 2026
• Fermentation, meat, seafood, eggs, dairy and ingredients, state of the industry, Good Food Institute
• GRAS notice inventory, US Food and Drug Administration
• Build the Strategy Before the Brand, Brighter Future, 2026